DrugDashboards

Creon

Pancrelipase · PANCRELIPASE LIPASE 36000 [USP'U]/1; PANCRELIPASE AMYLASE 180000 [USP'U]/1; PANCRELIPASE PROTEASE 114000 [USP'U]/1 · Capsule, Delayed Release Pellets · Oral · AbbVie Inc.

NDC 00032-3016-12 · 1 BOTTLE in 1 CARTON / 12 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE · BLA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00032-3016-13) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$12.72per unit
middle half $12.54–$13.35 · 5,347 plans · Apr 1, 2026
Est. net of rebatesⓘ
$7.63–$9.54
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
97%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for pancrelipase (oral solid) in the next 90 days

sole-source market · price up 2% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $1,926.88 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
BLA020725
TE code
—
Approval date
—
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedMar 15, 2021
    Cardinal Health Inc. — CGMP Deviations: Intermittent exposure to temperature excursion during storage.
  • Class II · TerminatedSep 15, 2014
    AbbVie Inc — Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000.

Manufacturers of Pancrelipase (Capsule, Delayed Release Pellets)

LabelerStrengthFirst seenLast seen
Abbott Laboratories GmbHPANCRELIPASE LIPASE 36000 [USP'U]/1; PANCRELIPASE PROTEASE 114000 [USP'U]/1; PANCRELIPASE AMYLASE 180000 [USP'U]/1Aug 20, 2026Sep 3, 2026
Abbott Laboratories GmbHPANCRELIPASE LIPASE 24000 [USP'U]/1; PANCRELIPASE PROTEASE 76000 [USP'U]/1; PANCRELIPASE AMYLASE 120000 [USP'U]/1Aug 20, 2026Sep 3, 2026
Abbott Laboratories GmbHPANCRELIPASE LIPASE 3000 [USP'U]/1; PANCRELIPASE PROTEASE 9500 [USP'U]/1; PANCRELIPASE AMYLASE 15000 [USP'U]/1Aug 20, 2026Sep 3, 2026
Abbott Laboratories GmbHPANCRELIPASE LIPASE 12000 [USP'U]/1; PANCRELIPASE PROTEASE 38000 [USP'U]/1; PANCRELIPASE AMYLASE 60000 [USP'U]/1Aug 20, 2026Sep 3, 2026
Abbott Laboratories GmbHPANCRELIPASE LIPASE 6000 [USP'U]/1; PANCRELIPASE PROTEASE 19000 [USP'U]/1; PANCRELIPASE AMYLASE 30000 [USP'U]/1Aug 20, 2026Sep 3, 2026
AbbVie Inc.PANCRELIPASE AMYLASE 60000 [USP'U]/1; PANCRELIPASE LIPASE 12000 [USP'U]/1; PANCRELIPASE PROTEASE 38000 [USP'U]/1Jul 15, 2026Sep 3, 2026
AbbVie Inc.PANCRELIPASE LIPASE 24000 [USP'U]/1; PANCRELIPASE PROTEASE 76000 [USP'U]/1; PANCRELIPASE AMYLASE 120000 [USP'U]/1Aug 26, 2026Sep 3, 2026
Fournier Laboratories Ireland LTDPANCRELIPASE LIPASE 36000 [USP'U]/1Jul 15, 2026Sep 2, 2026
AbbVie Inc.PANCRELIPASE AMYLASE 30000 [USP'U]/1; PANCRELIPASE LIPASE 6000 [USP'U]/1; PANCRELIPASE PROTEASE 19000 [USP'U]/1Jul 15, 2026Aug 31, 2026
AbbVie Inc.PANCRELIPASE LIPASE 36000 [USP'U]/1; PANCRELIPASE AMYLASE 180000 [USP'U]/1; PANCRELIPASE PROTEASE 114000 [USP'U]/1Aug 26, 2026Aug 31, 2026
AbbVie Inc.PANCRELIPASE LIPASE 180000 [USP'U]/1; PANCRELIPASE AMYLASE 36000 [USP'U]/1; PANCRELIPASE PROTEASE 114000 [USP'U]/1Jul 22, 2026Aug 22, 2026
AbbVie Inc.PANCRELIPASE LIPASE 120000 [USP'U]/1; PANCRELIPASE PROTEASE 24000 [USP'U]/1; PANCRELIPASE AMYLASE 76000 [USP'U]/1Jul 22, 2026Aug 22, 2026
Abbott Laboratories GmbHPANCRELIPASE LIPASE 60000 [USP'U]/1; PANCRELIPASE PROTEASE 12000 [USP'U]/1; PANCRELIPASE AMYLASE 38000 [USP'U]/1Jul 22, 2026Aug 19, 2026
Abbott Laboratories GmbHPANCRELIPASE LIPASE 120000 [USP'U]/1; PANCRELIPASE PROTEASE 24000 [USP'U]/1; PANCRELIPASE AMYLASE 76000 [USP'U]/1Jul 22, 2026Aug 19, 2026
Abbott Laboratories GmbHPANCRELIPASE LIPASE 15000 [USP'U]/1; PANCRELIPASE PROTEASE 3000 [USP'U]/1; PANCRELIPASE AMYLASE 9500 [USP'U]/1Jul 22, 2026Aug 19, 2026
Abbott Laboratories GmbHPANCRELIPASE LIPASE 180000 [USP'U]/1; PANCRELIPASE PROTEASE 36000 [USP'U]/1; PANCRELIPASE AMYLASE 114000 [USP'U]/1Jul 22, 2026Aug 19, 2026
Abbott Laboratories GmbHPANCRELIPASE LIPASE 30000 [USP'U]/1; PANCRELIPASE PROTEASE 6000 [USP'U]/1; PANCRELIPASE AMYLASE 19000 [USP'U]/1Jul 22, 2026Aug 19, 2026
AbbVie Inc.PANCRELIPASE AMYLASE 180000 [USP'U]/1; PANCRELIPASE LIPASE 36000 [USP'U]/1; PANCRELIPASE PROTEASE 114000 [USP'U]/1Jul 15, 2026Jul 19, 2026
Abbott Laboratories GmbHPANCRELIPASE AMYLASE 120000 [USP'U]/1; PANCRELIPASE LIPASE 24000 [USP'U]/1; PANCRELIPASE PROTEASE 76000 [USP'U]/1Jul 15, 2026Jul 15, 2026
Abbott Laboratories GmbHPANCRELIPASE AMYLASE 30000 [USP'U]/1; PANCRELIPASE LIPASE 6000 [USP'U]/1; PANCRELIPASE PROTEASE 19000 [USP'U]/1Jul 15, 2026Jul 15, 2026
Abbott Laboratories GmbHPANCRELIPASE AMYLASE 15000 [USP'U]/1; PANCRELIPASE LIPASE 3000 [USP'U]/1; PANCRELIPASE PROTEASE 9500 [USP'U]/1Jul 15, 2026Jul 15, 2026
Abbott Laboratories GmbHPANCRELIPASE AMYLASE 180000 [USP'U]/1; PANCRELIPASE LIPASE 36000 [USP'U]/1; PANCRELIPASE PROTEASE 114000 [USP'U]/1Jul 15, 2026Jul 15, 2026
Abbott Laboratories GmbHPANCRELIPASE AMYLASE 60000 [USP'U]/1; PANCRELIPASE LIPASE 12000 [USP'U]/1; PANCRELIPASE PROTEASE 38000 [USP'U]/1Jul 15, 2026Jul 15, 2026
AbbVie Inc.PANCRELIPASE AMYLASE 120000 [USP'U]/1; PANCRELIPASE LIPASE 24000 [USP'U]/1; PANCRELIPASE PROTEASE 76000 [USP'U]/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Creon — NDC 00032-3016-12," retrieved September 3, 2026, https://drugdashboards.com/drug/00032301612.

Free to cite with attribution — see how the data is put together.